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Recombinant adeno-assodated  virus 2 (AAV) virions were constructed containing a gene for 
resistance to neomycin (neoa), under the control of either the herpesvirus thymidine kinase (TK) 
gene promoter (vTK-Neo),  or the human parvovirus B19 p6 promoter (vB19-Neo), as well as 
those containing an upstream erythroid cell-specific enhancer (HS-2) from the locus control region 
of the human fl-globin gene cluster (vHS2-TK-Neo; vHS2-B19-Neo). These recombinant virions 
were used to infect either low density or highly enriched populations  of CD34 + cells isolated 
from human umbilical cord blood. In donogenic assays initiated with cells infected with the 
different recombinant AAV-Neo virions, equivalent high frequency transduction of the neo p" gene 
into slow-cycling multipotential, erythroid, and granulocyte/macrophage (GM) progenitor cells, 
including those with high proliferative potential, was obtained without prestimulation with 
growth factors, indicating that these immature and mature hematopoietic progenitor cells were 
susceptible to infection by the recombinant AAV virions. Successful transduction did not require 
and was not enhanced by prestimulation of these cell populations with cytokines. The functional 
activity of the transduced neo gene was evident by the development  of resistance to the drug 
G418, a neomycin analogue. Individual high and low proliferative colony-forming unit (CFU)-GM, 
burst-forming unit--erythroid, and CFU-granulocyte erythroid macrophage megakaryocyte colonies 
from mock-infected, or the recombinant virus-infected cultures were subjected to polymerase 
chain reaction analysis using a neo-specific synthetic oligonucleotide primer pair. A 276-bp DNA 
fragment that hybridized with a neo-spedfic  DNA probe on Southern blots was only detected 
in those colonies cloned from the recombinant virus-infected calls, indicating stable integration 
of the transduced  neo gene. These studies suggest  that parvovirus-based vectors may prove to 
be a useful alternative to the more commonly used retroviral vectors for high efficiency gene 
transfer into slow or noncycling primitive hematopoietic progenitor cells, without the need for 
growth factor stimulation, which could potentially lead to differentiation  of these calls before 
transplantation. 
p arvoviruses are among the smallest of the DNA-containing 
viruses that infect a wide variety of vertebrates (1, 2). Two 
parvoviruses of human origin, the adeno-associated virus 2 
(AAV)  1, and the parvovirus  B19, have been studied exten- 
sively (3, 4). AAV has thus far not been shown to be associated 
1 Abbreviations used in this paper: AAV, adenc~associated  virus 2; AAV-2H, 
human AAV-2; Ad2, human adenovirus 2; BFU-E, burst-forming unit 
erythroid; Epo, erythropoietin; LDCB, low density mononuclear cord 
blood; SLF, steel factor. 
with any known human disease (5, 6). Although the wild- 
type (wt) AAV genome has been documented to integrate 
via its inverted terminal repeats (ITRs) into human chro- 
mosomal DNA in a site-specific manner (7-9), this is appar- 
ently not the case with the recombinant AAV genomes. Par- 
vovirus B19, on the other hand, is now known to be the 
etiologic agent of a variety of clinical disorders in humans 
(10-15), and has been shown to have a remarkable tropism 
for human erythroid cells (16-20). We have described the con- 
struction of an AAV-B19 hybrid genome in which we corn- 
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and have speculated that this hybrid parvovirus may be a useful 
vector for gene transfer in human bone marrow cells (21). 
AAV-based vectors, in particular,  have recently attracted 
attention largely due to the fact that in contrast to retroviruses, 
the wt AAV is a nonpathogenic virus, and although the site- 
specific integration of the AAV genome into the human chro- 
mosome does not apparently lead to insertional mutagenesis 
(22), this remains to be established with the recombinant AAV. 
Furthermore,  the relatively higher stability, viral titers and 
transduction dfidency of AAV add to the desirable features 
of these types of vectors (23-25). Indeed, using the recom- 
binant AAV vector systems, regulated high level expression 
of the human ~/-globin in the K562 erythrolenkemia cell line 
in vitro has been accomplished (26). In addition, near-total 
suppression in vitro of HIV-1 gene expression and replica- 
tion in established cell lines using a similar vector system has 
recently been documented (27). Despite these advances, data 
are lacking on the feasibility of using the parvovirns-based 
vectors for transducing primary normal human diploid cells, 
specifically primitive human hematopoietic stem and progen- 
itor cells, believed to be ideal targets for somatic cell gene 
therapy. 
Human umbilical cord blood, which contains hematopoi- 
etic stem/progenitor cells at a frequency equal to or greater 
than that of adult bone marrow (28, 29), and with a high 
quality for proliferation  (30-34) and self-renewal capacity, 
as estimated by replating colonies in vitro (30, 31, 35), has 
shown promise clinically as an alternative source of human 
transplantable  and marrow-repopulating  cells (36-43).  He- 
matopoietic stem and progenitor calls in human cord blood 
may be ideal targets as recipients of potential gene therapy 
for hematopoietic disorders (44). We have recently demon- 
strated AAV-mediated gene transduction in rapid cycling he- 
matopoietic progenitor cells in murine bone marrow (45). 
In this report, we present data to suggest that it is feasible 
to achieve high efficiency gene transfer into slow or noncy- 
cling primary primitive and more mature human hemato- 
poietic progenitor cells using the recombinant  AAV-based 
vector system without first inducing  a higher  proliferative 
state with growth factor stimulation. These studies may have 
important implications for human gene therapy of hemato- 
poietic disorders. 
Materiah and Methods 
Cells, Viruses, and Plasmids.  A clonal population  of a human 
naso-pharyngeal cardnoma cell line, KB, was obtained from Dr. 
A. C. Antony (Indiana University School of Medicine) and main- 
tained as monohyer cultures in Eagle's MEM supplemented with 
10% fetal bovine serum. Human AAV-2 (AAV-2H), and human 
adenovirus 2 (Ad2) viral stocks were provided by Drs K. I. Berus 
(Coruell University Medical College, New York) and K. H. Fife 
(Indiana University School of Medicine), respectively, and grown 
in KB cells as previously described (46-48).  Human cord blood, 
scheduled for discard, was collected from the placental umbilical 
vein of normal,  healthy infants immediately after birth at Indiana 
University Hospitals  (Indianapolis, IN). 
Recombinant  AAV (49, 50) and B19 (51) plasmids have been 
described, and were obtained from Dr. K. J. Samulski (University 
of Pittsburgh,  Pittsburgh, PA) and Dr. P. "lhttersall (Yale Univer- 
sity School of Medicine, New Haven, CT), respectively.  Two recom- 
binant plasmids containing the neo  R gene have also been described 
(52, 53), and were obtained respectively from Drs. S. H. Larsen 
and K. H. Schloemer (Indiana University School of Medicine). A 
recombinant phsmid, pHS-2, containing the DNase I-hypersensitive 
site 2 from the human ~-globin gene cluster (54) was provided 
by Dr. Tim Townes (University of Alabama, Birmingham,  AL). 
Cell Separation Techn~ues.  Low density mononudear cord blood 
(LDCB; <1.077 g/cm  ~) cells were obtained by density centrifu- 
gation using Ficoll-Hypaque (Pharmada Fine Chemicals, Piscataway, 
NJ). LDCB cells were enriched for hematopoietic progenitor  cell 
populations  using CD34 column separation as follows. Nonad- 
herent, low density, T-lymphocyte-depleted cord blood cells (31) 
were incubated with biotinyhted CD34 antibody, resuspended at 
a concentration of 100-200  x  10  ~ cells/m1, and processed through 
an avidin-immuno2fllnity column (Ceprate TM System; CellPro, 
Inc., BotheR, WA). These cells, analyzed by flow cytometry on 
a FACSCan  |  (Becton Dickinson  &  Co.,  Mountain  View, CA) 
showed a CD34 + purity range between 80 and 98%. Cell viability 
(trypan blue exclusion) was consistently  >95%. 
Hematopoietic Progenitor Cell Assays.  LDCB or CD34 + cord 
blood cells were tither mock infected, or exposed to each recom- 
binant AAV-Neo  virus separately at a multiplicity-of-infection (moi) 
of 1 at 37~  for 2 h, washed with sterile PBS, pH 7.0, and sus- 
pended at various concentrations (usually 1-2.5  x  104 LDCB, and 
200-300 CD34 § cells/ml) in 35-ram plastic tissue culture dishes 
(Costar Data Packaging, Cambridge,/viA) containing tither 1 U/ml 
of recombinant human erythropoiefin (EPO), or Epo plus 100 U/m1 
of recombinant human IL-3 and 100 U/ml of recombinant human 
GM-CSF, or Epo + 1D3 + GM-CSF and 50 ug/rul of recombinant 
human steel factor (SLF) in 1.1% methylcellulose in IMDM. Unless 
otherwise indicated, the cells were not prestimulated with growth 
factors before viral infections.  In some experiments,  ceils were 
incubated with II.-3+GM-CSF+SLF  for 48 h before viral infec- 
tions. The presence of SLF in cultures allows detection of earlier 
subsets of stem/progenitor cells (29-31). These cell-plating con- 
centrations allowed clear detection of individual colonies with no 
overlap with other colonies. IL-3, GM-CSF, and SLF were kind 
gifts from Immunex Corp. (Seattle, WA) and EPO was purchased 
from Amgen, Inc. (Thousand  Oaks,  CA).  Some assays received 
200-1,000/~g/ml of G418 (Geniricin; Sigma Chemical Co., St. 
Louis, MO) into dishes within 1 d after cells had been plated in 
the presence of growth factors. Geniticin was dissolved at a final 
active concentration  of 4 mg/ml in IMDM, the pH was adjusted 
to 7.2 with 1 N NaOH, faltered through 0.22-pan falters (schleicher 
& Schuell, Keene, NH), and stored  frozen in 5-ml  aliquots  at 
-20~  The cultures were incubated at 37~  in a 100% humidified 
atmosphere of 5% CO2 at lowered (5%) Oz. After 14 d, burst- 
forming  unit-erythroid  (BFU-E) and CFU-GM and mixed cell 
(CFU-grannlocyte erythroid macrophage megakaryocyte [GEMM]) 
colonies were scored in situ with an inverted microscope using 
standard criteria for their identification  (28-31). 
Construction of Recombinant Plasmids and Virions.  The overall 
strategy for the construction  of the recombinant AAV containing 
the herpesvirus thymidine kinase OK) promoter-driven  neo  ~ gene 
(vTK-Neo) from a recombinant phsmid, designated pWP-8A, has 
been described recently (25, 45), and is illustrated in Fig. 1 A. Simi- 
larly, a recombinant plasmid containing the HS-2 enhancer upstreara 
of the TK promoter was constructed as shown in Pig. 1 B. Briefly, 
plasmid pWP-19 was cleaved with KPOI, and plasmid pHS-2 was 
cleaved with AatII and HinclI to isolate the HS-2 enhancer ele- 
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iigated with BgllI-cleaved  plasmid pWP-19 after treatment with 
PoRK to generate a plasmid designated  pSZ-16. Recombinant AAV 
virions (vHS2-B19-Neo) were generated as described above. The 
viral titers were determined on quantitative DNA dot blots as pre- 
viously described (17, 56). 
PCR Amplification, and Southern Blot AnalTsis.  Individual colo- 
nies (CFU-GM, BFU-E, and CFU-GEMM) from mock-infected, 
or recombinant AAV-neo virus-infected cultures were subjected to 
35-cycle PCR amplification using a neo-specific  synthetic oligonu- 
cleotide  primer pair (5'-TGAAGAGCTTGGCGGCG~Y and 
5'-GC~GAAGAACTCCAGCA]~AG-Y). Amplified  DNA prod- 
ucts were electmphoresed on 1.5% agarose gels and analyzed on 
Southern blots using a neo DNA probe as previously  described  (25, 
45, 53). Plasmids pTwu.G1 and pUC19 were used as positive and 
negative controls, respectively. 
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Figure  1.  Construction  of the recombinant AAV-Neo plasmids and 
virions. The strategy  for construction of the recombinant AAV virions 
containing a gene for resistance to tetracycline  (~R) and a gene for resis- 
tance to neomycin  (neo  ~) driven  by the herpesvirus thymidine  kinase  pro- 
moter (vTg-Neo;  A) has been described  recently  (25). The HS-2 enhancer 
element was inserted  upstream of the TK promoter to generate  a recom- 
binant AAV genome (vH$2-TK.Neo; B) as described in Materials and 
Methods. Similarly,  recombinant  AAV virions  containing  a gene  for resis- 
tance to ampidllin (Ap  ~) and the neoR gene driven by the parvovirus 
B19p6 promoter (vBl9-Neo; C), or those containing  an upstream HS-2 
enhancer  element  (vH$2-B19-Neo;  D) were  constructed  as described  above. 
All recombinant  genomes  were rescued  from  their  respective  plasmids  and 
packaged separately as previously  described (25, 45). 
ment. These DNA fragments were ligated together after treatment 
with PORK to generate a plasmid designated  pSZ-14. Recombinant 
virions  (vHS2-TK-Neo) were generated as described above. A 
plasmid containing the neo  R gene driven by the human parvovirus 
B19 promoter (p6) was constructed as depicted  in Fig. 1 C. Plasmid 
pYT104 was cleaved with EcoRI and XbaI, and a 277-bp DNA 
fragment containing the B19p6 promoter was cloned  between EcoRI 
and XbaI sites of  phsmid pUC19 by the standard  methods described 
in Sambrook et al. (55) to generate a plasmid designated, pB19p6. 
A 1.5-kb DNA fragment containing the neo  R gene was isolated 
from plasmid pTwu.G1 after digestion with BglII and BamHI, 
treated with POllK, and blunt-end-ligated  with HinclI-deaved 
pB19p6 to generate a recombinant phsmid, designated pBN-7. 
This plasmid was linearized by digestion with EcoRI and ligated 
to EcotLl-deaved  plasmid pAS203 containing the AAV-ITR.s (21). 
This resulted in a plasmid, designated pBN-8. Recombinant AAV 
virions (vB19-Neo) were generated as described above. Finally, 
a recombinant plasmid containing the B19p6-neo  ~ with an up- 
stream HS-2 enhancer was constructed as illustrated in Fig. 1 D. 
The HS-2 enhancer  dement was ligated  at the EcoRI site to generate 
a phsmid designated  pHS2-B19p6. The HS2-B19p6 DNA fragment 
was isolated by digesting this plasmid with AatII and HincII, and 
Results 
Sensitivity of  Cord Blood Progenitors to G418.  Before deter- 
mining the efficiency of AAV-mediated transduction of cord 
blood progenitors, the sensitivity of the different progenitor 
ceU classes to inhibition by G418 was assessed. As shown in 
Fig.  2, the different progenitor call classes differed in their 
sensitivity to inhibition by G418. Within the CFU-GM com- 
partment, those ceils responsive to stimulation by the com- 
bination of Epo  +  IL-3  +  GM-CSF  +  SLF (believed to 
be a more immature subset of CFU-GM) were less sensitive 
to inhibition by G418 than were the more mature subsets 
of CFU-GM (those responsive to stimulation by Epo +  IL- 
3  +  GM-CSF). Within the BFU-E compartment, the same 
age-related sensitivity to G418 was noted such that the subset 
of BFU-E responsive to stimulation by Epo  +  IL-3 +  GM- 
CSF was less sensitive to inhibition by the drug than the more 
mature subset of BFU-E responsive  to stimulation by Epo 
alone.  As previously noted (29),  when cord blood cells are 
plated in the presence of EPO  +  SLF _+  IL-3 and GM-CSF, 
CFU-GEMM but not BFU-E colonies are detected (data not 
shown). Next to the subset of CFU-GM responsive to stim- 
ulation by the combination of Epo  +  IL-3  +  GM-CSF  + 
SLF, the CFU-GEMM responsive to this same combination 
of growth factors was the least sensitive to inhibition by G418. 
Based on the information shown in Fig. 2, active concentra- 
tions of 600 and 800 #g/ml of G418 were chosen to estimate 
G418-resistant  progenitors of AAV-transduced cells. 
Recombinant AAV-mediated Transduction of  LDCB Cells, and 
Stable Integration of the neo Gen~  Equivalent numbers of 
mock-infected, or the recombinant AAV-Neo virus-infected 
cells were assayed for primitive as well as more mature hema- 
topoietic progenitor cells in semi-solid media in the presence 
of G418 as described in Materials and Methods. These data, 
derived from experiments with four different cord blood 
samples, either in the absence (Fig. 3 A), or the presence (Fig. 
3 B) of SLF, are depicted in Fig. 3. As is evident, whereas 
'~12% of the CFU-GM colonies derived from mock-infected 
cultures survived the G418-treatment at a final active con- 
centration of 600/~g/ml of the drug, the percent survival 
of the CFU-GM colonies cloned from the recombinant AAV- 
Neo virions was as follows: 25% with vTK-Neo, 38% with 
vHS2-TK-Neo, 39% with vB19-Neo,  and 27% with vHS2- 
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Figure  2.  Comparative analysis of the sen- 
sitivity of cord blood progenitors to G418- 
inhibition  of colony  formation.  104  LDCB 
cells were plated  -/+  G418 in the presence 
of either Epo, Epo +  IL-3 + GM-CSF, or Epo 
+  Ib3 +  GM-CSF + SLF, and the sensitivity 
of  CFU-GM-,  BFU-E-,  and  CFU- 
GEMM-derived colonies  to  G418 assessed. 
Results  are based on an average of three ex- 
periments  each  with  mean control  (-G418) 
colony numbers for CFU-GM (Epo  + 11.23 + 
GM-CSF), CFU-GM (E~ + IL.3 + GM-CSF 
+ 8LF), BFU-E (Epo), BFU-E (Epo+lL.3  + 
GM-CSF), and CFU-GEMM (Epo  + IL.3  + 
GM-CSF + SLF), respectively, ranging from 
9 to 50,  16 to 40,  9 to 33,  22 to 63, and 36 
to 72 in the individual  experiments. 
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B19-Neo, respectively.  A similar pattern with the BFU-E colo- 
nies was also observed. In the presence of SLF, m15% of the 
CFU-GM colonies from mock-infected cultures were resis- 
tant at a final active concentration of 800/~g/ml of G418, 
and 37-49% of these colonies cloned from the various recom- 
binant virus-infected cultures were resistant to G418. Under 
these assay conditions,  no BFU-E colonies were obtained, 
but the pattern of the CFU-GEMM colony formation was 
similar to that of the CFU-GM colony formation. For all 
the data in Fig. 3, colony formation by cells transduced with 
the different recombinant AAV-Neo vectors was similar 
>0.05), but significantly different than the mock-transduced 
control group ~  <0.05). 
We also wished to document the physical presence of the 
recombinant AAV-Neo virus-mediated transduction of the 
neo p" gene, presumably stably integrated with the chromo- 
somal DNA, in CFU-GM, BFU-E, and CFU-GEMM colo- 
nies. Five individual colonies each for CFU-GM, BFU-E, and 
CFU-GEMM analysis were picked from mock-infected,  or 
recombinant AAV-Neo virus-infected cultures, either in the 
absence (Fig. 3 A), or the presence (Fig. 3 B), of SLF, and 
evaluated using a neo-specific  oligonucleotide primer pair in 
a PCR amplification system. These data from one represen- 
tative experiment are presented in Fig. 4.  As can be seen, 
a 276-bp DNA fragment that hybridized with a neo-spedfic 
DNA probe on Southern blots could be detected in CFU- 
GM, BFU-E, and CFU-GEMM colonies cloned from the 
Figure  3.  Transduction of the neo  ~ gene in LDCB progenitor cells and 
hematopoietic  progenitor cell assays. Approximately 2.5  x  104 LDCB 
cells, after mock infection  (open ban),  or infection with the recombinant 
AAV-Neo virions (closed bars) at a moi of I, were plated in methylcellulose 
either in the absence (,4) or in the presence (B) of SLF, and exposed to 
a final active concentration  of 600 and 800/~g/ml of G418, respectively. 
CFU-GM, BPU-E, and CFU-GEMM-derived colonies were enumerated 
as described in Materials and Methods.  These data are the average results 
from four separate experiments. 
1870  Adeno-associated Virus-mediated  Gene Transfer in Human Umbilical Cord Blood Cells Figure  4.  Southern blot analysis of the PCR-amplified neo gene-spedfic DNA fragments from myeloid and erythroid colonies. Day 14 CFU-GM 
and BFU-E or CFU-GM and CFU-GEMM colonies derived either in the absence (A), or in the presence (B) of SLF, from mock-infected (lanes I-5), 
vTK-Neo virus-infected (lanes 6-10), vHS2-TK-Neo virus-infected (lanes 11-15), vB19-Neo virus-infected (lanes 16-20), and vHS2-B19-Neo virus- 
infected (lanes 21-25) cultures were individually picked and used in PCR amplification reactions as described in Materials and Methods. Plasmids pUC19 
and pTwu.G1 were used as negative and positive controls, respectively. The PCR products were analyzed on Southern blots using a neo-spedfic DNA 
probe. (Arrows) 276-bp neo-specific DNA fragment. 
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primitive as well as more mature hematopoietic progenitor 
cells infected by the recombinant  AAV-Neo virus.  In none 
of the colonies derived from mock-infected cells, could a neo- 
specific DNA product be amplified by PCK under identical 
conditions.  Taken together, these data suggest that both im- 
mature and mature subsets of hematopoietic progenitor cells 
in cord blood cells can be successively transduced,  and that 
high efficiency transduction of human hematopoietic progen- 
itor cells is indeed possible using the recombinant AAV-based 
virions. 
Lack of Requirement for Prestimulation with Growth Factors 
forAAV-mediated Transduction.  We next wished to examine 
the effect of prestimulation  of cord blood progenitor  cells 
with  various  growth  factors before  transduction  with  the 
recombinant AAV virions. In this experiment, three separate 
cord blood samples were either mock infected or infected at 
time zero (  T  =  0),  with  the vTK-Neo virions or allowed 
to incubate the presence ofIL-3  +  GM-CSF  +  SLF at 37~ 
for 48  h  (T  =  48),  followed by mock infection  with  the 
vTK-Neo virions under identical conditions.  Progenitor cell 
assays were carried out as described above. These data are shown 
in Fig.  5.  In each case, the colonies  grown from viraUy in- 
fected cells were significantly enhanced compared with the 
mock-infected cells (p <0.05).  As is evident, whereas the ex- 
Figure  5.  Effect  ofprestimulatinn with growth factors  on AAV-mediated 
transduction of LDCB cells. Approximately 2.5  ￿  104 LDCB ceils were 
mock ~  (open  Mrs)  or infected with the recombinant vTK-Neo  virions 
(closed ban) at a moi of 1 without growth factor prestimulation at time 
zero (T =  0), or incubated in the presence of IL-3 +  GM-CSF  +  SLF 
for 48 h (T = 48), followed  by mock infection or infection with the vTK- 
Neo virions under identical conditions. Cells were plated in methylcellu- 
lose either in the absence (A), or in the presence (B) of SLF, and exposed 
to a final active concentration of 600 and 800/~g/ml of G418, respectively. 
CFU-GM, BFU-E, and CFU-GEMM--derived  colonies were enumerated 
as described in Materials and Methods. These data are from three separate 
experiments. 
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factor prestimulation ranged between 33 and 86%  among 
the three cord blood samples, it was not significantly different 
from that when cells were prestimulated with growth factors 
for 48 h,  which ranged between 26  and 62%  (p >0.05). 
Similar patterns were obtained for the BFU-E and the CFU- 
GEMM colonies. We conclude from these data that unlike 
in retroviral-mediated transduction, prestimulation with ex- 
ogenously added growth factors is not a prerequisite for suc- 
cessful, high efficiency  transduction by the AAV-based  vector 
system. 
Successful  Transduction of CD34 + Cells.  It was next of in- 
terest to examine whether highly enriched CD34 + hema- 
topoietic cord blood progenitor cells could also be transduced 
with the recombinant AAV-Neo virions in the absence of 
drug selection. Clonogenic assays were carried out under a 
variety of conditions that yielded progeny cell colonies from 
primitive subsets of hematopoietic progenitors  as described 
in Materials and Methods.  For each of the assay conditions, 
eight to nine individual CFU-GM and CFU-GEMM colo- 
nies were picked and subjected to PCIL amplification as de- 
scribed above. The representative data for one of the sets in 
which the assays  were carried out in the presence of Epo + 
IL-3  +  GM-CSF  +  SLF are shown in Fig. 6. 
As is evident, whereas none of the colonies from mock- 
infected cultures demonstrated a neo-hybridizing DNA frag- 
ment, such a fragment could be readily amplified in 33-75% 
of  the colonies  cloned from the recombinant AAV-Neo  virions. 
Since subsets of  hematopoietic  progenitor ceils in cord blood 
are in relatively slow cycle (57) compared with those in adult 
human bone marrow, and since these cells were not preex- 
posed to growth factors in vitro to enhance their prolifera- 
tive status before viral infections, these results suggest that 
the relatively slow or noncycling hematopoietic progenitor 
cell populations in cord blood are susceptible to infection by 
the recombinant AAV virions. 
Figure 6.  Southern blot analysis  of the PCK-amplified neo gene-specific 
DNA  fragments  from  colonies cloned  from  CD34  +  cells. Individual 
CFU-GM colonies (lanes 1-9) and CFU-GEMM colonies (lanes 10-17) 
derived from CD34 + cells after either mock infection, or infections with 
the recombinant  AAV-Neo virions, were subjected to PCR amplification 
and Southern blot analyses essentially as described in the legend to Fig. 
4. Approximately  54% of the colonies were positive for the neo gene. 
Discussion 
Although retroviral vectors have been used in human gene 
therapy (58), the fear remains that the use of  retroviruses may 
be associated with the development of  neoplastic events (59). 
Since several DNA virus-based vectors, such as herpesvirus 
and adenovirus, may also suffer from a similar problem, the 
search for alternative vectors remains an important effort. It 
is interesting to note that a unique group of single-stranded 
DNA-containing viruses, the parvoviruses, have to date not 
been shown to be associated  with any malignant disease  (4-6). 
In fact, the wt AAV has been shown to possess antionco- 
genic properties in vitro as well as in vivo (60--63). Since AAV 
is nonpathogenic,  it has emerged as a potentially useful alter- 
native vector system (23-25),  although it remains to be es- 
tablished whether the recombinant AAV is also nonpatho- 
genic. However, since ~90%  of the human population is 
seropositive for AAV (5), accidental infection by recombinant 
AAV virions  in vivo may not be problematic. 
Employing the recombinant AAV vector system, a number 
of recent studies (26, 27, 64) have  reported successful trans- 
duction of exogenous sequences in established cell lines that 
are frequently aneuploid.  In our studies, we chose to focus 
on infection  of primary human diploid  cells since normal 
diploid cells are both the most likely target of a natural AAV 
infection (47, 48), and are the likely recipients of potential 
gene therapy with this vector system (22). In this report, 
we examined the efficacy  of  the AAV-based vector system for 
transduction of a population of human umbilical cord blood 
cells that contains hematopoietic stem and progenitor cells 
(28-35).  High efficiency transduction of CD34 + cells and 
expression of the transduced  neo  ~  gene in the progeny of 
these primitive and more mature hematopoietic cells suggest 
that the AAV vector system might prove useful in a gene 
therapy setting. 
In this context, it is noteworthy that high efficiency  trans- 
duction of CD34 + cells from human umbilical cord blood 
cells has been obtained with retroviral vectors (44, 65). In 
those experiments, cord blood cells were first exposed to po- 
tent combinations of  growth factors to place the progenitors 
into a higher cell cycle state before exposing the cells to the 
retroviral vectors. In contrast, the data presented herein dem- 
onstrate high efficiency  transduction into slow or noncycling 
immature and mature human hematopoietic progenitors from 
cord blood in the absence of  growth factor stimulation using 
the recombinant AAV-based vector system without further 
enhancement, even when the cells are prestimulated  with 
growth factors. For retroviruses, at least one round of cell 
division seems to be required before random integration of 
a transduced  gene (66). AAV-mediated transduction may 
thus be potentially advantageous, compared with retrovirus- 
mediated transduction, in not requiting preincubation of  cells 
in the presence of growth factors for stable gene integration. 
Incubation of  cells with growth factors may lead to differen- 
tiation of some of the more immature cells responsible for 
long-term engraftment. This potential problem may be ob- 
viated by the use of AAV for gene transduction. 
It is intriguing that in our present studies we were unable 
1872  Adeno-associated Virus-mediated Gene Transfer in Human Umbilical Cord Blood Cells to obtain lineage-specific expression of the neo  P" gene driven 
by the B19p6 promoter, given the remarkable erythroid cell 
tropism of the parvovirus B19 (16-21, 67). In our previous 
infection studies with a recombinant AAV-B19 hybrid virus, 
expression from this promoter was largely restricted to cells 
in the erythroid lineage, and to a lesser extent, in the mega- 
karyocytic lineage (21, 56). After infections with the recom- 
binant  virions,  we also did not detect expression from the 
B19p6 promoter in nonerythroid  human cells  (our unpub- 
lished data). Although Liu et al. (68) have presented evidence 
of expression from this promoter in established cell lines in 
vitro, those studies were carried out with plasmid transfec- 
tions. We speculate that our observed results may be due to 
the application  of a selective pressure.  Further  studies will 
be needed to establish the underlying molecular mechanism 
of the erythroid cell-specific expression from the B19p6 pro- 
motet during nonselective viral infections. Similar strategies 
may nonetheless be employed by using tissue-specific promoters 
to limit expression of a transduced gene in a given cell type 
(69). Further in vivo studies with nonhuman primate model 
systems are warranted  to evaluate the safety as well as the 
ei~cacy of the AAV-based vector system before its potential 
use in human  gene therapy. 
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